BioGaia AB (FRA:BGLA)
€ 9.115 -0.035 (-0.38%) Market Cap: 931.59 Mil Enterprise Value: 835.03 Mil PE Ratio: 31.83 PB Ratio: 6.64 GF Score: 95/100

Q2 2020 Biogaia AB Earnings Call Transcript

Aug 13, 2020 / 07:30AM GMT
Release Date Price: €10.84 (+0.74%)
Operator

Ladies and gentlemen, welcome to the BioGaia second quarter 2020 report. (Operator Instructions) Today, I'm pleased to present Isabelle Ducellier, CEO. Madam, please go ahead.

Isabelle Valerie Ghislaine Ducellier;publ;CEO;President
BioGaia AB

()-&

Thank you so much. And dear investor, Alex and I wish you welcome to BioGaia Q2 report. I hope you had nice holiday despite the special circumstances I will call it. So from the top line point of view, we have a good quarter, with a total sales increasing by 10%, mainly thanks to the increase of the sales in pediatric. If we look at pediatric product, the main SKU and the main increase comes from our drops.

If we look at the Adult segment, it is driven mainly by Prodentis, or oral health probiotics and by gastric tablet. I will come back to that later. All our 2 regions are showing a growth at different pace with modest 1% for EMEA and a very strong double digit, both for APAC and for Americas.

Next page, please. Obviously, as for Q1, unfortunately

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot